Myriad Genetics (MYGN) closed at $4.21 on October 19, 2026, up 5.8% from the previous close, on volume of 1,321,209 shares (30-day average 1,913,567).
Data as of October 19, 2026.
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
PRNewswire (Thu, 8-Oct 9:01 AM ET)
Globe Newswire (Thu, 8-Oct 9:00 AM ET)
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Globe Newswire (Wed, 16-Sep 8:00 AM ET)
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
Globe Newswire (Thu, 27-Aug 9:05 AM ET)
Business Wire (Thu, 13-Aug 8:00 PM ET)
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Mon, 10-Aug 10:07 AM ET)
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
Business Wire (Sat, 8-Aug 2:57 PM ET)
Globe Newswire (Fri, 7-Aug 2:54 PM ET)
Globe Newswire (Thu, 6-Aug 10:09 AM ET)
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Myriad Genetics trades on the NASDAQ stock market under the symbol MYGN.
As of October 19, 2026, MYGN stock price climbed to $4.21 with 1,321,209 million shares trading.
MYGN has a beta of 0.09, meaning it tends to be less sensitive to market movements. MYGN has a correlation of 0.00 to the broad based SPY ETF.
MYGN has a market cap of $397.61 million. This is considered a Small Cap stock.
Last quarter Myriad Genetics reported $191 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-15 million and missed earnings estimates by -$.19.
In the last 3 years, MYGN traded as high as $29.30 and as low as $2.74.
The top ETF exchange traded funds that MYGN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
MYGN has underperformed the market in the last year with a price return of -47.9% while the SPY ETF gained +17.2%. MYGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.0% and -7.3%, respectively, while the SPY returned +2.4% and -0.4%, respectively.
MYGN support price is $3.80 and resistance is $4.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYGN shares will trade within this expected range on the day.
